DNA Link

Pentagrit is a zebrafish discovery lab offering efficacy screening services. Facilities includes state of art zebrafish facility for pre-clinical development across segments Oncology, Inflammation, Gene Therapy, Metabolic and Cardiovascular, Neurology and Infectious diseases.

Zebrafish Gene Therapy Programme
Immunogenicity Optimizer for Vector and Target DNA

Zebrafish Tumor Programme
Diffuse Intrinsic Pontine Glioma
Pancreatic Tumor
(NSCLC) Lung Cancer
Leukemia

Zebrafish Metabolic Programme
Left Ventricular Hypertrophy
Type II Diabetes
Obestity
NASH and NAFLD

Zebrafish Neuronal Programme
Parkinson’s
Alzheimer’s
Multiple Sclerosis

Zebrafish Rare Disease Programme
RETT Syndrome
Batten Disease

Zebrafish Pain Programme
Intestinal Pain
Peripheral Pain

Zebrafish Inflammation Programme
Arthritis
Psoriasis

Zebrafish Infection Programme
Dengue
Malaria
Chikungunya
Sars CoV-2

Avesthagen Limited - Brief Summary

Avesthagen is a leading systems biology life science company uniquely positioned to help solve some of the world’s biggest healthcare and environmental challenges. Since its inception 20 years ago, Avesthagen has introduced new ideas, technologies, and products, for the life sciences market.
The Avestagenome Project® is Avesthagen’s largest epidemiological study ever conducted in India, and the first such detailed system biology study worldwide on an endogamous population. The project has collected a biobank of Parsi blood samples with extensive patient data from 4,500 members and investigates the molecular basis of longevity and age-related disorders, prioritizing cancers, cardiovascular disease, diabetes and neurological disorders.
Recognizing the importance of the Parsi cohort and the unique systems’ biology approach to research, the U.S.-based Foundation for a Smoke-Free World, whose mission is to end smoking within this generation, recently awarded a grant to Avesthagen Limited® to prioritize research into lung and tobacco-related cancers. Avesthagen will combine liquid biopsy, next-generation sequencing (NGS), state- of-the-art bioinformatics, artificial intelligence and machine learning to identify predictive and early-stage biomarkers of cancers in smokers. The project will use non-Parsi smoker and non-smoker samples from the wider Indian and other populations to gain further insights into the evidence behind such data.
Avesthagen is expected to be a key player in the lucrative personalised medicine market, which is projected to reach a value of US $1.7 trillion by 2026.

Today, Avesthagen is proud to build on this heritage by partnering with others to tackle unprecedented challenges now facing our world. We believe we can provide enough healthy food for people everywhere and protect the environment for generations to come.

Holypharm Biotech specialized in active pharmaceutical ingredients and intermediates. With our head-office in the capital of Zhejiang Province: Hangzhou. We have participations and contracts with 2 plants located Zhejiang and Jiangsu Province. Our main products are cardiovasculars, antidiabetes, anti-cancer. Our products have been registered in Latin America, India, North-America, Turkey, etc..

To provide clients with more technology support, we will present efficient regulatory documents to show professional abilities in this field. We are experts in quality control, registration data, excellent packaging & labeling and logistics.

HOLYPHARM (PHARM DEPT.) - Our main products are cardiovasculars, antidiabetes, anti-cancer, steroid, antibiotics, anti-HIV and their intermediates, especially on cardiovascular and antibiotics.

HOLYPHARM (VETERINARY DEPT.)-All our manufacture bases and facilities are GMP approved, we provide more than 100 veterinary products, forms including raw material ( ferment and synthesize products), premix, injection, tablets, suspension etc..

WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec’s open-access platform is enabling more than 4,100 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that "every drug can be made and every disease can be treated."

Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented Pharma Company with presence in 55 countries. Indoco, a USD 166 million company, employs over 6000 people including over 300 skilled scientists.

The Company has 9 manufacturing facilities, 6 for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by various regulatory authorities such as USFDA, UK-MHRA, DRU Botswana, PMDA-Japan, TGA-Australia, FMHACA-Ethiopia, DPML- Ivory Coast, SAHPRA- South Africa, NDA-Uganda, etc.

Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infective, Stomatologicals, Ophthalmic, Nutritionals,  Cardiovascular, Anti-Diabetics, Pain Management  etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital,  Sensoform, Sensodent-KF, Cloben-G, Glychek, Kidodent, Carmicide, Rexidin, MCBM, Methycal, etc. On the international front, Indoco has tie-ups with large generic companies across the globe.

Indoco has carved a place for itself in the international arena and is exporting a number of generic products in the Regulated and Emerging Markets. Indoco’s branded formulations are promoted in Emerging Markets of South East Asia, Africa, Latin America and CIS countries. The Company participates in various tenders floated by authorities from different countries. Indoco has tie-ups with large generic companies across the globe and works in close coordination with its customers for leveraging core competencies.

Indoco Analytical Solutions division has been carved to serve customers for their analytical research needs. AnaCipher CRO, Hyderabad, is a USFDA inspected facility providing clinical trial solutions, BA/BE/Phase I/Phase studies.